Q4
1.6.2022 15:02:07 CEST | Business Wire | Press release
Q4 Inc. (TSX: QFOR) (“Q4”), a leading capital markets communications platform provider, is excited to announce the launch of Q4 Capital Connect ™, a revolutionary, scalable platform built to streamline workflows and provide data-driven strategic insights across the capital markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005573/en/
Q4 Capital Connect™ enables public companies across all industries and market caps to seamlessly launch and measure the impact of a complete investor relations strategy. With one place to launch how they communicate their value to the markets, analyze the impact of every outreach, target and engage with the right investors, IR teams can build a repeatable, proactive strategy to connect with the capital markets. The platform approach allows all data generated by investors across an IR program to be aggregated alongside shareholder analytics for insights to shape a communication strategy that investors value while identifying and prioritizing the shareholders that matter.
The Q4 Capital Connect platform will house a portfolio of future applications, purpose-built to empower capital markets professionals. The first of these applications include Q4 Engagement Analytics and Q4 Web Management .
The Engagement Analytics application on Q4 Capital Connect™ aggregates the actions of investors and shareholders visiting an investor relations website and IR-related events, turning behavioral data into powerful leading indicators of stock movement, ownership data and surveillance to drive a new and proactive approach to investor targeting. Through these analytics, IROs can identify which new, existing or targeted institutions are assessing content, analyze interactions at the early stages of an investor’s research, prioritize their management team’s time to proactively engage with the right investor, and accelerate management’s awareness of activist interest in the company.
Engagement Analytics is the first product in the market that uniquely combines investor behavior with the buying and selling of publicly traded securities. This provides the ability to understand investors’ actions and intent on a daily basis and takes proactive targeting to a new level.
The fully integrated Web Management application on Q4 Capital Connect™ provides a frictionless and simplified approach to managing an IR website, offering one destination to request, track and approve critical updates to the market. Q4’s secure platform connects users with the Q4 Content Services team to easily request, preview, and publish changes to their website, while tracking change history in the same place. To date there are over 1,300 Q4 clients already using the web management application, who have experienced up to a 57% reduction in interactions when requesting content updates, a 35% improvement in turnaround times, and a vastly improved overall user experience.
“The launch of Q4 Capital Connect™ is just the beginning of a transformational approach to drive strategic, efficient and more effective interactions across the capital markets,” said Darrell Heaps, Q4’s CEO. “Built on proprietary data and analytics, along with an ever increasing portfolio of digital communication solutions, Q4 Capital Connect is a scalable platform that will continue to expand to an increasing number of applications for investor relations, as well as key workflows for investment banks and investors. We are very excited to introduce Q4 Capital Connect™ and demonstrate the strategic value and efficiencies we can provide to all capital markets participants when they come onto the Q4 platform.”
To learn more about Q4 Capital Connect™ please click here .
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors and investment banks make decisions to efficiently discover, communicate and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets CRM, shareholder and market analytics tools. The firm is a trusted partner to more than 2,700 public companies globally including many of the most respected brands in the world. Q4 is based in Toronto, with offices in New York and London. Learn more at q4inc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005573/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom